John Charles Canning Purchases 4,375 Shares of Femasys (NASDAQ:FEMY) Stock

Femasys Inc. (NASDAQ:FEMY) COO John Charles Canning purchased 4,375 shares of the company’s stock in a transaction on Friday, August 7th. The stock was acquired at an average cost of $3.20 per share, for a total transaction of $14,000.00. Following the completion of the purchase, the chief operating officer owned 4,375 shares of the company’s stock, valued at approximately $14,000. This trade represents a ? increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Femasys Trading Down 0.8%

Shares of FEMY stock traded down $0.02 during trading hours on Tuesday, hitting $2.35. 228,436 shares of the company were exchanged, compared to its average volume of 120,035. The firm has a market cap of $7.10 million, a P/E ratio of -0.44 and a beta of -2.08. Femasys Inc. has a fifty-two week low of $2.29 and a fifty-two week high of $22.20. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.98 and a current ratio of 3.91. The company has a 50 day simple moving average of $3.87 and a two-hundred day simple moving average of $7.49.

Femasys (NASDAQ:FEMY) last released its quarterly earnings data on Friday, May 8th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($1.33) by $1.43. Femasys had a negative net margin of 521.97% and a negative return on equity of 258.08%. The company had revenue of $0.42 million during the quarter, compared to analyst estimates of $0.77 million.

Institutional Trading of Femasys

Hedge funds and other institutional investors have recently bought and sold shares of the business. Kovack Advisors Inc. acquired a new position in Femasys during the fourth quarter worth $27,000. HRT Financial LP acquired a new position in shares of Femasys during the fourth quarter valued at about $30,000. Cetera Investment Advisers acquired a new position in shares of Femasys during the fourth quarter valued at about $36,000. Osaic Holdings Inc. bought a new stake in shares of Femasys during the second quarter worth about $45,000. Finally, State Street Corp increased its position in shares of Femasys by 43.5% during the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after acquiring an additional 24,500 shares in the last quarter. Institutional investors own 65.27% of the company’s stock.

Analysts Set New Price Targets

FEMY has been the subject of several research analyst reports. Weiss Ratings raised shares of Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Wall Street Zen upgraded Femasys to a “hold” rating in a research note on Saturday, June 13th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $80.00.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.